Pliant Therapeutics Inc (PLRX) - Stock & Dividends

Pliant Therapeutics, Inc., listed on the NASDAQ under the ticker symbol PLRX, is a biopharmaceutical company based in South San Francisco, California. Established in 2015, the company focuses on discovering, developing, and commercializing innovative treatments for fibrosis and associated ailments within the United States.

One of Pliant Therapeutics' flagship products is bexotegrast, an oral medication that functions as a dual selective inhibitor of avß6 and avß1 integrins. Currently, this potential therapy is undergoing three Phase IIa trials targeting conditions such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

In addition to bexotegrast, Pliant Therapeutics is actively working on other promising treatments like PLN-1474, a selective inhibitor designed for addressing liver fibrosis linked to nonalcoholic steatohepatitis, as well as PLN-101095, a compound targeting solid tumors. Furthermore, the company is developing PLN-101325 for individuals affected by muscular dystrophies.

For more information about Pliant Therapeutics, Inc. and their research projects, visit their official website at https://pliantrx.com.